MYGN Q4 2024 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q4 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$211M+7.1% YoY

Gross Profit

$151M71.7% margin

Operating Income

-$39M-18.5% margin

Net Income

-$43M-20.2% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

-1.3%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$700,000

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$327M

Stockholders' Equity

$701M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$211M	$197M	+7.1%
Gross Profit	$151M	$135M	+11.8%
Operating Income	-$39M	-$31M	-24.2%
Net Income	-$43M	-$31M	-36.2%

Geographic Segments

UNITED STATES

$196M93%

Non-US

$15M7%